544 related articles for article (PubMed ID: 17594783)
1. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Davidson DF; Grosset K; Grosset D
Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
[TBL] [Abstract][Full Text] [Related]
2. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
4. Age-related medical decision limits for urinary free (unconjugated) metadrenalines, catecholamines and metabolites in random urine specimens from children.
Davidson DF; Hammond PJ; Murphy D; Carachi R
Ann Clin Biochem; 2011 Jul; 48(Pt 4):358-66. PubMed ID: 21670092
[TBL] [Abstract][Full Text] [Related]
5. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Maruyama W; Naoi M; Narabayashi H
J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
[TBL] [Abstract][Full Text] [Related]
6. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Isobe C; Abe T; Terayama Y
J Clin Neurosci; 2010 Jun; 17(6):717-21. PubMed ID: 20356746
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
8. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa.
Agil A; Durán R; Barrero F; Morales B; Araúzo M; Alba F; Miranda MT; Prieto I; Ramírez M; Vives F
J Neurol Sci; 2006 Jan; 240(1-2):31-6. PubMed ID: 16219327
[TBL] [Abstract][Full Text] [Related]
9. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
Rajda C; Dibó G; Vécsei L; Bergquist J
Neuroimmunomodulation; 2005; 12(2):81-4. PubMed ID: 15785109
[TBL] [Abstract][Full Text] [Related]
10. Disturbed intracortical excitability in early Parkinson's disease is l-DOPA dose related: a prospective 12-month paired TMS study.
Bares M; Kanovský P; Rektor I
Parkinsonism Relat Disord; 2007 Dec; 13(8):489-94. PubMed ID: 17449315
[TBL] [Abstract][Full Text] [Related]
11. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.
Uchiyama T; Sakakibara R; Hattori T; Yamanishi T
Mov Disord; 2003 May; 18(5):573-8. PubMed ID: 12722172
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
[No Abstract] [Full Text] [Related]
13. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
[TBL] [Abstract][Full Text] [Related]
14. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
15. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
[TBL] [Abstract][Full Text] [Related]
17. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
18. [Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients].
Vasil'ev VN
Vopr Med Khim; 1980; 26(6):782-6. PubMed ID: 6779421
[TBL] [Abstract][Full Text] [Related]
19. [Pseudopheochromocytoma in Parkinson disease and depression].
Jähnel M
Psychiatr Prax; 2003 May; 30 Suppl 2():S64-5. PubMed ID: 14509040
[TBL] [Abstract][Full Text] [Related]
20. Changes in urinary excretion of catecholamines and their metabolites in pediatric dental patients.
Sakuma N; Nagasaka N
ASDC J Dent Child; 1996; 63(2):118-22. PubMed ID: 8708120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
